[go: up one dir, main page]

PE20020373A1 - FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS - Google Patents

FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS

Info

Publication number
PE20020373A1
PE20020373A1 PE2001000889A PE2001000889A PE20020373A1 PE 20020373 A1 PE20020373 A1 PE 20020373A1 PE 2001000889 A PE2001000889 A PE 2001000889A PE 2001000889 A PE2001000889 A PE 2001000889A PE 20020373 A1 PE20020373 A1 PE 20020373A1
Authority
PE
Peru
Prior art keywords
flavor
compositions
lopinavir
flavoring
water
Prior art date
Application number
PE2001000889A
Other languages
Spanish (es)
Inventor
Laman Alani
Donald P Gauwitz
John M Lipari
Kennan C Marsh
Vanik D Petrossian
Richard H Whelan
Soumojeet Ghosh
Dilip Kaul
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PE20020373A1 publication Critical patent/PE20020373A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)

Abstract

SE REFIERE UNA COMPOSICION LIQUIDA QUE COMPRENDE a)SISTEMA SABORIZANTE QUE COMPRENDE: i)DE 20% A 67% DE EDULCORANTES COMO JARABE DE MAIZ DE ALTA FRUCTOSA; ii)DE 1,4% A 3,5% DE INGREDIENTES SABORIZADOS COMO CRISTALES DE MENTOL, ACEITE DE MENTA, VAINILLA, SABOR A ALGODON DE AZUCAR, CARAMELO, iii)MODIFICADORES DEL SABOR COMO CITRATO DE SODIO, CLORURO DE SODIO, ACIDO CITRICO, b)AGENTES FARMACEUTICOS ACTIVOS COMO LOPINAVIR, RITONAVIR c)UN SISTEMA DE SOLVENTES QUE COMPRENDE SOLUBILIZANTES COMO AGUA, ALCOHOLES ALQUILICOS (ETANOL), ALQUILENGLICOLES (PROPILENGLICOL); d)UN AGENTE ESPESANTE COMO POLIVINILPIRROLIDONA; e)MEJORADOR DE LA BIODISPONIBILIDAD COMO DERIVADO DE ACEITE DE CASTOR. TAMBIEN SE REFIERE A UN PROCESO PARA LA PREPARACION. LOS SISTEMAS SABORIZANTES PUEDEN MEJORAR LAS COMPOSICIONES LIQUIDAS QUE CONTIENEN RITONAVIR O LOPINAVIR QUE SON PRACTICAMENTE INSOLUBLES EN AGUA Y TIENDEN A TENER UN SABOR AMARGOREFERRED TO A LIQUID COMPOSITION THAT INCLUDES a) FLAVORING SYSTEM THAT INCLUDES: i) FROM 20% TO 67% OF SWEETENERS AS HIGH FRUCTOSE CORN SYRUP; ii) FROM 1.4% TO 3.5% OF FLAVORED INGREDIENTS LIKE MENTHOL CRYSTALS, MINT OIL, VANILLA, COTTON CANDY FLAVOR, CANDY, iii) FLAVOR MODIFIERS LIKE SODIUM CITRATE, SODIUM CHLORIDE, CITRIC ACID , b) ACTIVE PHARMACEUTICAL AGENTS SUCH AS LOPINAVIR, RITONAVIR c) A SOLVENT SYSTEM THAT INCLUDES SOLUBILIZERS SUCH AS WATER, ALKYL ALCOHOLS (ETHANOL), ALKYLENE GLYCOLS (PROPYLENE GLYCOL); d) A THICKENING AGENT SUCH AS POLYVINYLPYRROLIDONE; e) BIOAVAILABILITY IMPROVER AS A DERIVATIVE FROM CASTOR OIL. IT ALSO REFERS TO A PROCESS FOR PREPARATION. FLAVORING SYSTEMS CAN IMPROVE LIQUID COMPOSITIONS CONTAINING RITONAVIR OR LOPINAVIR WHICH ARE PRACTICALLY INSOLUBLE IN WATER AND TEND TO HAVE A BITTER FLAVOR

PE2001000889A 2000-09-05 2001-09-04 FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS PE20020373A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65519200A 2000-09-05 2000-09-05

Publications (1)

Publication Number Publication Date
PE20020373A1 true PE20020373A1 (en) 2002-05-13

Family

ID=24627898

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000889A PE20020373A1 (en) 2000-09-05 2001-09-04 FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS

Country Status (10)

Country Link
EP (1) EP1315487A2 (en)
JP (1) JP2004522698A (en)
AR (1) AR030715A1 (en)
AU (1) AU2001288695A1 (en)
BR (1) BR0108433A (en)
CA (1) CA2417258A1 (en)
MX (1) MXPA03001952A (en)
PE (1) PE20020373A1 (en)
UY (1) UY26925A1 (en)
WO (1) WO2002020057A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
JP5767429B2 (en) 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド Crystallization inhibitors in solid dispersants
KR20050061604A (en) * 2002-11-22 2005-06-22 피르메니히 에스아 Oral compositions which mask the salty taste of salts
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
GB2423711B (en) * 2005-10-24 2007-02-14 Fortune Apex Dev Ltd Method for preparing a pharmaceutical composition with enhanced mucoadhesion
WO2013129436A1 (en) * 2012-02-29 2013-09-06 武田薬品工業株式会社 Oral agent
US8771651B2 (en) * 2012-09-10 2014-07-08 Johnson & Johnson Consumer Companies, Inc. Mouth rinses and tooth sensitivity treatment compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
WO1997046222A1 (en) * 1996-06-03 1997-12-11 Merck & Co., Inc. Pediatric formulation for hiv protease inhibitors

Also Published As

Publication number Publication date
WO2002020057A2 (en) 2002-03-14
UY26925A1 (en) 2002-04-26
JP2004522698A (en) 2004-07-29
AU2001288695A1 (en) 2002-03-22
CA2417258A1 (en) 2002-03-14
WO2002020057A3 (en) 2002-05-10
EP1315487A2 (en) 2003-06-04
AR030715A1 (en) 2003-09-03
BR0108433A (en) 2006-06-06
MXPA03001952A (en) 2003-09-10

Similar Documents

Publication Publication Date Title
PE20020373A1 (en) FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS TO MAKE SUCH COMPOSITIONS
CN101621997B (en) Pharmaceutical composition
EP2735305B1 (en) Stabilised liquid pharmaceutical preparations
EP1543826B1 (en) Concentrated aqueous solution of ambroxol
NO950134L (en) Formulations for orally administered pharmaceutical agents
PE20030545A1 (en) RIBAVIRIN SYRUP FORMULATIONS
EP0315332B1 (en) Antitussive liquid compositions containing phenol
JPH10502616A (en) Method for stabilizing DX-52-1 compound and freeze-dried composition thereof
US7429390B2 (en) Stable pharmaceutical compositions, processes for making the same and methods of their use
ES2310550T3 (en) PREPARATION WATERPROOF LIQUID OF PRANOPROPHENE.
US5874450A (en) Intranasal formulations for promoting sleep and method of using the same
US6194462B1 (en) Pharmaceutical preparation containing nimesulide for oral administration
CN114555085B (en) Pharmaceutical composition comprising a thrombolytic peptide-tetrahydroisoquinoline conjugate
CA1253160A (en) Pharmaceutical salts of 4'-(9-acridinylamino) methanesulfon-manisidide
US4406888A (en) Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution
US6660743B1 (en) Therapeutic aqueous composition containing a hexahydro-5-pyrimidinamine compound and a polyalkoxylated fatty alcohol
JPH1135489A (en) Liquid agent that prevents decomposition of polyoxyethylene hydrogenated castor oils
ES2238418T3 (en) STABLE WATERY DEOXIFRUCTOSAZINE SOLUTION.
JP3990728B2 (en) N- [4-oxo-2- (1H-tetrazol-5-yl) -4H-1-benzopyran-8-yl] -4- (4-phenylbutoxy) benzamide salt
JPH0733666A (en) Stabilization of indolocarbazole derivatives
JP2003055247A (en) Liquid preparation for internal use
JP2007008852A (en) Method for stabilizing pravastatin-containing aqueous formulation
ES2356828T3 (en) PREPARED FOR DROPS THAT UNDERSTAND DIMENTINDENO.
GB1397893A (en) Pharmaceutical compositions
TH51212A (en) Flavoring systems for pharmaceutical components and methods for their preparation

Legal Events

Date Code Title Description
FX Voluntary withdrawal